The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 05, 2021
Filed:
May. 13, 2019
Applicant:
Xenon Pharmaceuticals Inc., Burnaby, CA;
Inventor:
Gregory N. Beatch, West Vancouver, CA;
Assignee:
Xenon Pharmaceuticals Inc., Burnaby, CA;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 37/00 (2006.01); A61K 31/215 (2006.01); A01N 37/12 (2006.01); A01N 37/44 (2006.01); A61K 31/24 (2006.01); A01N 25/00 (2006.01); A61K 31/472 (2006.01); A61P 25/08 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/472 (2013.01); A61K 9/0053 (2013.01); A61P 25/08 (2018.01);
Abstract
In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.